4.1 Article

Clinical and economic impact of oncology-trained pharmacist integration in an ambulatory cancer clinic

Journal

JOURNAL OF ONCOLOGY PHARMACY PRACTICE
Volume -, Issue -, Pages -

Publisher

SAGE PUBLICATIONS LTD
DOI: 10.1177/10781552231202221

Keywords

Oncology; pharmacist intervention; ambulatory clinic; cancer clinic; economic benefit; clinical impact; oncology pharmacist

Ask authors/readers for more resources

This study analyzed the clinical and economic benefits of introducing a board-certified oncology pharmacist into outpatient oncology practice. The results showed that pharmacist interventions reduced emergency department visits and inpatient admissions, resulting in cost avoidance and savings.
Introduction: Outpatient oncology practice is a growing area of opportunity for pharmacists to provide clinical services and evidence-based care. Methods: This single-center, retrospective chart review analyzed the clinical and economic benefits of a board-certified oncology pharmacist after integration into the ambulatory oncology clinic setting. Primary outcomes were total cost avoidance for pharmacist interventions and impact on Centers for Medicare and Medicaid Services (CMS) OP-35 measures. Pharmacist interventions were characterized into distinct types which were then assigned a cost avoidance value. Cost avoidance was calculated per hour and then extrapolated to a yearly estimate based on a 40-h work week for one year for one full-time equivalent pharmacist. Data collection for the primary clinical outcome was performed by compiling provider-specific emergency department (ED) and inpatient admission rates for diagnoses specified in CMS OP-35 measures within 30 days after receiving outpatient chemotherapy. The rates for the data collection period were compared to the rates six months prior to pharmacist integration to assess pharmacist impact. Results: In six months, 516 total interventions were made by the oncology pharmacist. The incidence of ED visits was 3.34% and 1.72% during the pre- and post-pharmacist intervention periods, respectively. The incidence of inpatient admissions was 2.43% and 0.34% pre- and post-pharmacist intervention, respectively. Total cost avoidance was estimated to be US$375,795 and when accounted for the median pharmacist salary at our institution, total cost savings was US$204,437. Conclusion: The presence of an oncology pharmacist specialist in the ambulatory cancer clinic provided clinical and economic benefits to the cancer clinic.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available